Current and future biomarkers in gastric cancer

被引：49

作者：

Abbas, Muhammad ^{[1
,2
,3
]}

Faggian, Alessia ^{[4
]}

Sintali, Dahiru Nasiru ^{[5
]}

Khan, Ghulam Jilany ^{[6
,7
,8
]}

Naeem, Shagufta ^{[9
]}

Shi, Meiqi ^{[2
,3
]}

Chen Dingding ^{[1
]}

机构：

[1] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Dept Clin Pharm, Nanjing 211198, Jiangsu, Peoples R China

[2] Nanjing Med Univ, Affiliated Canc Hosp, Dept Oncol, Jiangsu Canc Hosp, 42 Baiziting, Nanjing 210009, Jiangsu, Peoples R China

[3] Jiangsu Inst Canc Res, 42 Baiziting, Nanjing 210009, Jiangsu, Peoples R China

[4] Azienda ULSS 3 Serenissima, SS Giovanni & Paolo Reg Hosp, Reg Ctr Biomarkers, Dept Clin Pathol & Transfus Med, Campo SS Giovanni & Paolo 6777, I-30122 Venice, VE, Italy

[5] China Pharmaceut Univ, Sch Pharm, Dept Pharm, Nanjing 211198, Jiangsu, Peoples R China

[6] China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing 210009, Jiangsu, Peoples R China

[7] Univ Cent Punjab, Fac Pharm, Dept Pharmacol & Therapeut, Lahore, Pakistan

[8] Southeast Univ, State Key Lab Bioelect, Sch Biol Sci & Med Engn, Nanjing 210096, Jiangsu, Peoples R China

[9] Ayub Med Coll, Dept Pathol, Abbottabad 22040, Pakistan

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2018年 / 103卷

关键词：

Gastric cancer; Predictive biomarkers; Treatment; Signaling cascades; Response to treatments; Clinical significance; Emerging markers; GROWTH-FACTOR RECEPTOR; MULTICENTER PHASE-II; C-ERBB-2 PROTEIN EXPRESSION; E-CADHERIN; GENE AMPLIFICATION; MET EXPRESSION; LUNG-CANCER; FACTOR VEGF; C-MET; PROGNOSTIC-SIGNIFICANCE;

D O I：

10.1016/j.biopha.2018.04.178

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Gastric cancer is the fourth most common worldwide cause of cancer-related death. Early gastric cancer has no associated symptoms, for this reason, patients come to the attention of the clinicians only in advanced stages. This paper aims to give a global view on the biomarkers for gastric cancer and the therapy in use. We discuss VEGF family, HER family, E-cadherin, PD-L1, and PD-L2, FGFR, mTOR. Finally, we considered emerging biomarkers as MET, microsatellite instability, and microRNA variations. Furthermore, we have analyzed in depth the chemotherapeutic and adjuvant therapies used in the clinic nowadays, comparing the overall and progression-free survival between them. Identifying and validating diagnostic, prognostic, predictive, and pharmacodynamic biomarkers will be mandatory to the huge impact on patients' outcomes and for improving the efficiency of the drug development process.

引用

页码：1688 / 1700

页数：13

共 211 条

[1]

Abbas A., 2014, Cellular and molecular immunology E-book

[2] CLINICAL EVALUATION OF CEA, CA125, CA19-9 AND CA72-4 IN GASTRIC CANCER PATIENTS WITH ADJUVANT CHEMOTHERAPY [J].